Anna Gaya

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Real-world pegcetacoplan treatment of paroxysmal nocturnal hemoglobinuria patients with an unsatisfactory response to prior therapies.

Real-world pegcetacoplan treatment of paroxysmal nocturnal hemoglobinuria patients with an unsatisfactory response to prior therapies.

Journal: Hematology (Amsterdam, Netherlands)

Published: June 11, 2026

Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy.

Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy.

Journal: HemaSphere

Published: February 06, 2026

Half-dose glucarpidase: an effective rescue for toxic methotrexate plasma concentrations in a patient with bilateral primary vitreoretinal lymphoma.

Half-dose glucarpidase: an effective rescue for toxic methotrexate plasma concentrations in a patient with bilateral primary vitreoretinal lymphoma.

Journal: Annals of hematology

Published: December 02, 2025

Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.

Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.

Journal: The Lancet. Haematology

Published: January 13, 2025

Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH.

Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH.

Journal: Blood

Published: July 24, 2024

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.

Journal: The New England journal of medicine

Published: March 13, 2024

Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.

Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.

Journal: American journal of hematology

Published: February 29, 2024

Results of a phase 1/2 study of cemdisiran in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria.

Results of a phase 1/2 study of cemdisiran in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria.

Journal: EJHaem

Published: December 20, 2022

Pegcetacoplan: climbing up the complement cascade.

Pegcetacoplan: climbing up the complement cascade.

Journal: The Lancet. Haematology

Published: July 11, 2022

Cloudy fluid, cloudy diagnosis.

Cloudy fluid, cloudy diagnosis.

Journal: Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis

Published: January 21, 2022

Prolonged viral replication in patients with hematologic malignancies hospitalized with COVID-19.

Prolonged viral replication in patients with hematologic malignancies hospitalized with COVID-19.

Journal: Haematologica

Published: November 23, 2021

Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir.

Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: October 13, 2020

Showing 1-12 of 24

Last Updated: 09/26/2026